Brought to you by 
Valeant becomes white knight for Afexa; offers $Cdn73.3mm
18 Oct 2011
Executive Summary
Emerging as the white knight, Valeant Pharmaceuticals International Inc. (prescription and OTC drugs) has made a $Cdn73.3mm ($74.3mm) offer for public natural products maker Afexa Life Sciences Inc. Valeant would pay $Cdn0.71 in cash per share, 29% higher than the $Cdn0.55 unsolicited per-share bid made by Paladin Labs Inc. a few weeks ago. Valeant’s offer is also a 47% premium to Afexa’s ten-day average prior to Paladin’s hostile announcement.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Nutraceuticals
- OTC, Consumer
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Valeant becomes white knight for Afexa; offers $Cdn73.3mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice